3 Results for "

society

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "society" in MCE Product Catalog:

0.5 mL 96-Well Tube Rack
0.5 mL 96-Well Tube Rack
0 Images
Cat. No.: HY-E0225
compounds
0.5 mL 96-Well Tube Rack, compliant with the industry-standard SBS (Society for Biomolecular Screening) specifications. This product features a sliding lock mechanism on the lid to prevent tube dislodgement. The side of the rack is equipped with an identifiable barcode for easy compound storage and retrieval. The matching tube (HY-E0224) is made from the same material as this tube, effectively preventing uneven expansion issues during freeze-thaw cycles.
CNS MPO Lead-like Library
CNS MPO Lead-like Library
0 Images
Cat. No.: HY-L920
24,816 compounds
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. The CNS MPO (Multi-Parameter Optimization) score is a widely recognized algorithm in medicinal chemistry. Developed by Pfizer, this method is based on an analysis of approved CNS drugs and their interior CNS drug candidates, establishing the CNS MPO rules. It incorporates six key physicochemical properties (ClogP, ClogD, MW, TPSA, HBD, and pKa) to prospectively optimize CNS drug attributes—such as high blood-brain barrier (BBB) permeability, low P-gp efflux liability, low metabolic clearance, and high safety—thereby improving the clinical success rate of CNS drug candidates. The CNS MPO compound library is a collection of compounds with CNS MPO scores greater than 5, specifically designed for CNS drug discovery.
MCE CNS BBB Lead-like Library
MCE CNS BBB Lead-like Library
0 Images
Cat. No.: HY-L919
27,503 compounds

With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

Assay Types